Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
about
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.Anticancer potential of sanguinarine for various human malignancies.Drug Modulators of B Cell Signaling Pathways and Epstein-Barr Virus Lytic Activation.Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
P2860
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
@en
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
@nl
type
label
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
@en
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
@nl
prefLabel
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
@en
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
@nl
P2093
P2860
P1476
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
@en
P2093
C R Flowers
I B Greenwell
P2860
P304
P356
10.1080/14737140.2017.1285702
P577
2017-01-23T00:00:00Z